• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® ADPR Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • CD38 Assay System
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human CD38 Enzyme
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • GTPase Profiling Services
    • ATPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • RIPK2 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay System
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • p97 Assays – Application
      • Ketohexokinase Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
      • WRN Exonuclease Assays – Application
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Using a CD73 Activity Assay to Study the Adenosine Pathway and Cancer

by Bellbrook Labs / Wednesday, 11 September 2019 / Published in Emerging Targets
CD73 Activity Assay to Help Stop Cancer

Tumor Immunosuppression and a CD73 Activity Assay –  To say cancer is complex would be an understatement. From the cause, to treatment, to living with the disease, nothing about it is easy. As one of the leading factors of death worldwide and the burden on families and the healthcare system as a whole, it’s no wonder why scientists have been fighting cancer at all angles for decades. Cells can become cancerous when DNA is damaged or mutations occur. The number of genes that can be affected and contribute to cancer is astounding; from tumor suppressor genes to oncogenes (for example). And, even more, genes play a role once the cancer is established and metastases taking on an environment of its own unlike that of a normal cell.

Immunosuppressive Adenosine

Suppressing the immune response is one-way cancer cells can remain active and prolific, causing more harm to the individual with the disease. What if we could remove this suppression in order to stop cancer in its tracks? Adenosine suppresses the immune response in a myriad of ways and is abundant due to the inflammatory tumor conditions.1 When the tumor environment becomes deprived of oxygen, hypoxia-inducible factors (HIF) activate other members of the pathway such as CD73. This enzyme catalyzes the dephosphorylation of AMP to create adenosine.1 Specifically, hypoxic conditions release ATP which gets converted to AMP by CD39 and then CD73 comes in to generate adenosine.2 Therefore, targeting adenosine and/or CD73 has gained interest in treating cancer.

CD73 Inhibitor to the Rescue

A large amount of research has been done showing the relevance of the adenosine pathway to cancer and its progression. Additionally, several studies have examined the likelihood of blocking targets such as CD73 in order to abate the spread of disease. Indeed, CD73 has shown promise in blocking tumor progression.3 Corvus Pharmaceuticals is an example of this promise. The company consists of a group of scientists capitalizing on the inhibition of adenosine production thereby promoting anti-tumor immune responses leading to tumor regression.

Another exciting revelation is the possibility of being able to use CD73 as not only a treatment to cancer but a biomarker given the correlation between CD73 expression and the prognosis of oncologic patients.3 Overexpression of CD73 has been associated with a worse prognosis as well as chemotherapy resistance in cancer patients.3 

A CD73 Activity Assay to Aid in Future Research

There is still important research to be done and therapeutic potential in CD73 along with other proteins in the adenosine pathway. A CD73 activity assay can aid in this research and discovery. Recently scientists at BellBrook Labs developed an assay for CD73 by measuring adenosine produced by the enzyme. The method uses the Transcreener ADP² Assay along with a coupling enzyme to determine enzymatic activity. The assay allowed scientists to study the enzyme, perform dose-response curves, and even a 1,600 compound pilot screen. It is our hope the method will provide a simple, mix-and-read, HTS approach to accelerate drug discovery for institutions interested in CD73. The result of this work is presented a poster at the Discovery on Target 2019 Conference.

Learn More About the CD73 Assay

References

  1. Young A, Mittal D, Stagg J, Smyth MJ. Targeting cancer-derived adenosine: New therapeutic approaches. Cancer Discov. 2014;4(8):879-888. doi:10.1158/2159-8290.CD-14-0341 https://www.ncbi.nlm.nih.gov/pubmed/25035124
  2. Antonioli L, Haskó G, Fornai M, Colucci R, Blandizzi C. Adenosine pathway and cancer: where do we go from here? Expert Opin Ther Targets. 2014;18(9):973-977. doi:10.1517/14728222.2014.925883 https://www.ncbi.nlm.nih.gov/pubmed/24958495
  3. Riaz N, Wolden SL, Gelblum DY, Eric J. Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapy. HHS Public Access. 2016;118(24):6072-6078. doi:10.1002/cncr.27633. https://www.ncbi.nlm.nih.gov/pubmed/22707358
Tagged under: CD73 Assay

What you can read next

DDX1 as a versatile RNA Helicase
DDX1: A Versatile RNA Helicase
Targeting Host Kinases for Hepatitis C Treatment
ADP Detection: It’s not all about kinases

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Preview of DNA Damage Repair Webinar

    [Webinar] Targeting DNA Damage Repair for Drug Discovery Using the Transcreener ADPR® Assay

    Interested in DNA damage repair pathways for dr...
  • Calculating MAPK14 Residence Time

    Transcreener® ADP2 Assay Delivers Precise Measurement of Functional MAPK14 Residence Time

    Researchers at the University of Tubingen use T...
  • DDX1 as a versatile RNA Helicase

    DDX1: A Versatile RNA Helicase

    DDX1 (Dead-Box Helicase 1) belongs to the DEAD-...
  • RAB2 Transports Membrane Bound Vesicles

    Investigating RAB2 as a Vesicle Transporter & Autophagy Initiator

    RAB2 is part of the RAB family of small GTPases...
  • PARP1 as a Hero vs Villain

    Is PARP1 a Hero or Villain?

    Not counting histones, PARP1 [Poly(ADP-ribose) ...

Archives

BellBrook Labs
1232 Fourier Drive, Suite 115
Madison, Wisconsin 53717 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2023 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP